Suppr超能文献

从起始到侵袭阶段胰腺癌免疫反应的动态变化

Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

作者信息

Clark Carolyn E, Hingorani Sunil R, Mick Rosemarie, Combs Chelsea, Tuveson David A, Vonderheide Robert H

机构信息

Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

出版信息

Cancer Res. 2007 Oct 1;67(19):9518-27. doi: 10.1158/0008-5472.CAN-07-0175.

Abstract

The dynamics of cancer immunosurveillance remain incompletely understood, hampering efforts to develop immunotherapy of cancer. We evaluated the evolving in vivo immune response to a spontaneous tumor in a genetically defined mouse model of pancreatic ductal adenocarcinoma from the inception of preinvasive disease to invasive cancer. We observed a prominent leukocytic infiltration even around the lowest grade preinvasive lesions, but immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg), dominated the early response and persisted through invasive cancer. Effector T cells, however, were scarce in preinvasive lesions, found in only a subset of advanced cancers, and showed no evidence of activation. The lack of tumor-infiltrating effector T cells strongly correlated with the presence of intratumoral MDSC with a near mutual exclusion. In vitro, we found that MDSC suppressed T-cell proliferation. Overall, our results show that suppressive cells of the host immune system appear early during pancreatic tumorigenesis, preceding and outweighing antitumor cellular immunity, and likely contribute to disease progression. Thus, in contrast to the hypothesis that an early "elimination phase" of cancer immunosurveillance is eventually overwhelmed by a growing invasive tumor, our findings suggest that productive tumor immunity may be undermined from the start. Efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer.

摘要

癌症免疫监视的动态过程仍未完全被理解,这阻碍了癌症免疫疗法的开发。我们在一个基因定义的胰腺导管腺癌小鼠模型中,评估了从癌前病变开始到侵袭性癌症阶段,针对自发性肿瘤的体内免疫反应的演变。我们观察到,即使在最低级别的癌前病变周围也有明显的白细胞浸润,但包括肿瘤相关巨噬细胞、髓系来源的抑制细胞(MDSC)和调节性T细胞(Treg)在内的免疫抑制细胞在早期反应中占主导地位,并持续存在于侵袭性癌症阶段。然而,效应T细胞在癌前病变中很少见,仅在一部分晚期癌症中发现,且没有激活的迹象。肿瘤浸润性效应T细胞的缺乏与肿瘤内MDSC的存在密切相关,几乎相互排斥。在体外,我们发现MDSC抑制T细胞增殖。总体而言,我们的结果表明,宿主免疫系统的抑制细胞在胰腺肿瘤发生早期就出现了,先于抗肿瘤细胞免疫且数量超过后者,可能促进了疾病进展。因此,与癌症免疫监视早期的“清除阶段”最终被不断生长的侵袭性肿瘤压倒的假设相反,我们的研究结果表明,有效的肿瘤免疫可能从一开始就受到破坏。测试MDSC、肿瘤相关巨噬细胞和Treg的强效抑制剂,尤其是在疾病早期进行测试,是开发新型癌症免疫疗法的重要下一步。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验